Neo Ivy Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Neo Ivy Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-482	Closed	-$30K	–	580
2022 Q3	$30K	Sell	482 -2,047	-81%	-$143K	0.08%	268
2022 Q2	$201K	Sell	2,529 -2,733	-52%	-$259K	0.54%	60
2022 Q1	$554K	Buy	5,262 +5,204	+8,972%	+$507K	0.5%	55
2021 Q4	$6K	Buy	+58	New	+$6.33K	0.01%	400
2021 Q2	–	Sell	-1,037	Closed	-$95K	–	667
2021 Q1	$95K	Buy	+1,037	New	+$87.5K	0.1%	252
2020 Q4	–	Sell	-187	Closed	-$14K	–	635
2020 Q3	$14K	Buy	+187	New	+$12.9K	0.01%	424
2020 Q2	–	Sell	-11,127	Closed	-$330K	–	657
2020 Q1	$330K	Buy	+11,127	New	+$376K	0.54%	40
2019 Q2	–	Sell	-24,540	Closed	-$648K	–	455
2019 Q1	$648K	Buy	+24,540	New	+$582K	0.37%	130

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neo Ivy Capital Management's HZNP Position: Q4 2022 in Review

Neo Ivy Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 482 shares — an estimated $30K sold.

Neo Ivy Capital Management first reported a position in HZNP in Q1 2019 and held it in 8 quarters. The position peaked at $648K in Q1 2019. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Neo Ivy Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 482 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $30K.
Neo Ivy Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 8 quarters.
Neo Ivy Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $648K in Q1 2019.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Neo Ivy Capital Management's 13F filing for Q4 2022, filed 27 Mar 2023.